Amarin Corp Plc (AMRN)

[north40000]

Amarin’s launch of its generic would be for both indications like present Vascepa. Why do you think it odd that such a generic would “infringe” its patents? Following the observations of the 3-member CAFC panel in Amarin v. Hikma et al, Hikma’s product has NOT been FDA-approved for CVD indications, nor has it been shown to be therapeutically equivalent to Vascepa. The rub might be that a different dose or “container/capsule” environment might also require clinical trial testing by Amarin for both indications.